Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Core Insights - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for oncology and autoimmune diseases [3] Company Overview - Nurix's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B) [3] - The company is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline [3] - Nurix has partnered with Gilead, Sanofi, and Pfizer for drug discovery, retaining options for co-development and profit sharing in the U.S. [3] - The company utilizes an AI-integrated discovery engine and has expertise in ligase to enhance its clinical advancements [3] Upcoming Events - Arthur T. Sands, M.D., Ph.D., and Hans van Houte will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 [1] - The event will be webcast live and archived for 30 days [2]